SCHEMBL214255

SCHEMBL214255

[CH]1C=Nc2ccccc2S1

nearest known ligand 0.42

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10932771 0.76 TRPA1 (0.38) TRPA1
Iodide SCHEMBL7464181 0.76 TRPA1 (0.38) TRPA1
SCHEMBL620184 0.70 TRPA1 (0.41) TRPA1
SCHEMBL2516583 0.67 TRPA1 (0.38) TRPA1
SCHEMBL6799856 0.67 TRPA1 (0.42) TRPA1
SCHEMBL7384086 0.66 TRPA1 (0.46) TRPA1
SCHEMBL8369709 0.66 TRPA1 (0.46) TRPA1
SCHEMBL7350695 0.63 LMNA (0.43) TRPA1
SCHEMBL29394860 0.62 TRPA1 (0.32) TRPA1
SCHEMBL30218263 0.62 TRPA1 (0.32) TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1420644-B1 SUBSTITUTED PROPARGYLAMINES BAYER CROPSCIENCE SA (FR) 2006-05-31 EP claimed
CN-115210273-B Process for controlling the formation of ziegler-natta procatalyst particles and use for olefin polymerization 布拉斯科美国公司 2024-07-12 CN disclosed
US-20240174776-A1 SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION W.R. GRACE & CO.-CONN. (US) 2024-05-30 US disclosed
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same SERINA THERAPEUTICS, INC. (US) 2024-03-12 US disclosed
US-20240043446-A1 ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE INTERVET INC. (US) 2024-02-08 US disclosed
US-20240043385-A1 ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE INTERVET INC. (US) 2024-02-08 US disclosed
EP-4308615-A1 SPHERICAL CATALYST COMPONENTS FOR OLEFIN POLYMERIZATION W. R. Grace & Co.-Conn (US) 2024-01-24 EP disclosed
CN-117355546-A Spherical catalyst component for olefin polymerization 格雷斯公司 2024-01-05 CN disclosed
EP-3464391-B1 NON-PHTHALATE DONOR FOR POLYOLEFIN CATALYSTS BRASKEM AMERICA INC (US) 2024-01-03 EP disclosed
US-20230382938-A1 ELECTROCHROMIC DEVICES HAVING A BUFFER SYSTEM GENTEX CORPORATION (US) 2023-11-30 US disclosed
WO-2002018383-A2 AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE CHIRON CORPORATION (US) 2002-03-07 WO disclosed
WO-2002016349-A1 4-, 5-, 6- AND 7-INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-02-28 WO disclosed
WO-2002008223-A1 INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS H. LUNDBECK A/S (DK) 2002-01-31 WO disclosed
US-5739130-A TREATING SYSTEMIC LUPUS ERYTHEMATOSIS, MELANOMA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-04-14 US disclosed
US-5583135-A TREATING SYSTEMIC LUPUS ERYTHEMATOSIS OR MELANOMA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-12-10 US disclosed
EP-0639182-A1 QUINOLINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-02-22 EP disclosed
EP-0625983-A1 HETEROTRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-30 EP disclosed
WO-1993015083-A1 HETEROTRICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-08-05 WO disclosed
WO-1992018483-A1 QUINOLINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-10-29 WO disclosed
EP-0120589-B1 IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043385-A1 ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE HRH4, PNPO, NME4 TRPA1 667/4885
US-20240043446-A1 ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE DHODH, NISCH, DDT TRPA1 212/4885
US-20230382938-A1 ELECTROCHROMIC DEVICES HAVING A BUFFER SYSTEM HCN2, HCN1, HCN3 TRPA1 1552/4885
US-11925689-B2 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same ERBB3, ERBB2, PANK2 TRPA1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.